Biosensors: DBS upgrades to Buy from Hold with TP$1.35 up from prev $1.13 on expected Japanese approval in BioMatrix. House observes that historically stents take an avg of 3 yrs for CE to approval in Japan and BioMatrix obtained its CE mark in 2008...
Apart from Japan, progress in other areas through mkt share gains and penetration with new product launches are growing well. Other positives include exploration in India and M&A opportunities.
No comments:
Post a Comment